Literature DB >> 11350182

Molecular and enzymatic characterization of a unique carnitine palmitoyltransferase 1A mutation in the Hutterite community.

C Prip-Buus1, L Thuillier, N Abadi, C Prasad, L Dilling, J Klasing, F Demaugre, C R Greenberg, J C Haworth, V Droin, N Kadhom, S Gobin, P Kamoun, J Girard, J P Bonnefont.   

Abstract

Hepatic carnitine palmitoyltransferase 1 (CPT1A) deficiency is a rare disorder of mitochondrial fatty acid oxidation inherited as an autosomal recessive trait. Symptomatology comprises attacks of hypoketotic hypoglycemia with risk of sudden death or neurological sequelae. Only one CPT1A mutation has been reported so far. Identification of the disease-causing mutations allows both insights into the structure-function relationships of CPT1A and management of the patients and their relatives. The molecular analysis of CPT1A deficiency in a large Hutterite kindred illustrates this point. Both cDNA and genomic DNA analysis demonstrate that the affected patients are homozygous for a 2129G>A mutation predicting a G710E substitution. Studies in fibroblasts from one patient as well as heterologous expression of the mutagenized CPT1A in yeast show that the G710E mutation alters neither mitochondrial targeting nor stability of the CPT1A protein. By contrast, kinetic studies conclusively establish that the mutant CPT1A is totally inactive, indicating that the G710E mutation dramatically impairs the catalytic function of CPT1A. Finally, due to a strongly suspected founder effect for the origin of CPT1A deficiency in this Hutterite kindred, identification of this disease-causing mutation allows the setup of a targeted DNA-based newborn screening in this at-risk population. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350182     DOI: 10.1006/mgme.2001.3176

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  18 in total

1.  Successful long-term treatment of hepatic carnitine palmitoyltransferase I deficiency and a novel mutation.

Authors:  J M Stoler; M A Sabry; C Hanley; C L Hoppel; V E Shih
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

2.  Demonstration of N- and C-terminal domain intramolecular interactions in rat liver carnitine palmitoyltransferase 1 that determine its degree of malonyl-CoA sensitivity.

Authors:  Audrey Faye; Karen Borthwick; Catherine Esnous; Nigel T Price; Stéphanie Gobin; Vicky N Jackson; Victor A Zammit; Jean Girard; Carina Prip-Buus
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

3.  Carnitine palmitoyltransferase IA polymorphism P479L is common in Greenland Inuit and is associated with elevated plasma apolipoprotein A-I.

Authors:  Chandheeb Rajakumar; Matthew R Ban; Henian Cao; T Kue Young; Peter Bjerregaard; Robert A Hegele
Journal:  J Lipid Res       Date:  2009-01-29       Impact factor: 5.922

4.  Structural model of carnitine palmitoyltransferase I based on the carnitine acetyltransferase crystal.

Authors:  Montserrat Morillas; Eduardo López-Viñas; Alfonso Valencia; Dolors Serra; Paulino Gómez-Puertas; Fausto G Hegardt; Guillermina Asins
Journal:  Biochem J       Date:  2004-05-01       Impact factor: 3.857

Review 5.  Carnitine palmitoyltransferase 1A P479L and infant death: policy implications of emerging data.

Authors:  Alison E Fohner; Nanibaa' A Garrison; Melissa A Austin; Wylie Burke
Journal:  Genet Med       Date:  2017-01-26       Impact factor: 8.822

Review 6.  The Mystery of Extramitochondrial Proteins Lysine Succinylation.

Authors:  Christos Chinopoulos
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

7.  Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis.

Authors:  Roberto Conti; Edoardo Mannucci; Pompeo Pessotto; Emanuela Tassoni; Paolo Carminati; Fabio Giannessi; Arduino Arduini
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

8.  Variants in CPT1A, FADS1, and FADS2 are Associated with Higher Levels of Estimated Plasma and Erythrocyte Delta-5 Desaturases in Alaskan Eskimos.

Authors:  V Saroja Voruganti; Paul B Higgins; Sven O E Ebbesson; John Kennish; Harald H H Göring; Karin Haack; Sandra Laston; Eugene Drigalenko; Charlotte R Wenger; William S Harris; Richard R Fabsitz; Richard B Devereux; Jean W Maccluer; Joanne E Curran; Melanie A Carless; Matthew P Johnson; Eric K Moses; John Blangero; Jason G Umans; Barbara V Howard; Shelley A Cole; Anthony Gean Comuzzie
Journal:  Front Genet       Date:  2012-06-11       Impact factor: 4.599

9.  Development of a diagnostic DNA chip to screen for 30 autosomal recessive disorders in the Hutterite population.

Authors:  Barbara Triggs-Raine; Tamara Dyck; Kym M Boycott; A Micheil Innes; Carole Ober; Jillian S Parboosingh; Alexis Botkin; Cheryl R Greenberg; Elizabeth L Spriggs
Journal:  Mol Genet Genomic Med       Date:  2016-01-19       Impact factor: 2.183

10.  Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of β-oxidation.

Authors:  Cong-Hui Yao; Gao-Yuan Liu; Rencheng Wang; Sung Ho Moon; Richard W Gross; Gary J Patti
Journal:  PLoS Biol       Date:  2018-03-29       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.